The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes, certainly a rollercoaster these last few weeks.
When I bought in, I genuinely thought wow this is an incredible opportunity for a ten or maybe twenty bagger with medium risk . The technology and the market position looked fantastic. A bit of time and patience seemed to be all that was required.
The badly worded performance update and today’s frankly ridiculous rns (sorry but biotech companies should be like Fort Knox on digital security) have made me wonder if this is just a bunch of scientists without any idea how to make money in the real world.
I now hope for a cheap buyout (5p ?)or a placing (dilute us in half?) which will give us the time we need to get to break even cash flow.
Woodstock, respect for your resilience and positivity.
But, as a fellow holder I’m sure you’ll agree this is a kick in the teeth we didn’t need just when we have a funding requirement coming up.
This is a great company and I’m hoping it’s going to deliver me an early retirement, but someone needs to get control of:
1. The ip - has someone just stolen our raisin d’etre in a cyber attack?
2. Our finances - we need a stable base to work from, without a heavy handed lender breathing down our necks every 6 months. I hope there’s a third party involved because our current cfo has zero experience of being a cfo never mind arranging finance for a rapidly growing biotech company.
This nonsense today has shaken my nerves to the core, I really hope we see the board steadying the ship in the coming days.
I genuinely don't care about dilution here, because the potential is massive and we only need a year or two to start to realise it.
What matters is keeping the lights on and remaining a going concern with publicly held shares.
The sooner the better for confirmation that there is a plan in place to achieve that.
Sorry no - this is a technology company, it shouldn't be in a position where it may have lost it ip to a competitor.
Another thing the company hasn't got a grip on unfortunately.
As a holder I'm massively disappointed by today's development.